Female cancer prediction using cervical omics to individualise screening and prevention

Projektinformationen

FORECEE

ID Finanzhilfevereinbarung: 634570

DOI 10.3030/634570

Projekt abgeschlossen

EK-Unterschriftsdatum 27 März 2015

Startdatum 1 September 2015

Enddatum 29 Februar 2020

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 7 994 746,25

EU-Beitrag € 7 994 746,25

Koordiniert durch

UNIVERSITY COLLEGE LONDON
United Kingdom

Leistungen

Documents, reports (6)

Recommendations for screening policy from legal/regulatory/ethical and women’s perspective
Review on decision-analytic cost-effectiveness

Review on decision-analytic cost-effectiveness studies in women’s cancers (based on current screening/prevention strategies) analysis publication available

Cost-effectiveness in women’s cancer (based on WID test projections) analysis publication available
Leaflet and results from survey and public workshop results
Screening/prevention recommendations based on the WID test available
Scientific publication on the optimal delivery of risk-stratified screening, including consensus guidelines on implementation plan

Websites, patent fillings, videos etc. (3)

Project website
Multimedia presentation available
Formal presentation to the ESGO patient advocacy group (ENGAGe)

Formal presentation to the ESGO patient advocacy group ENGAGe

Veröffentlichungen

Peer reviewed articles (7)

Epigenetic Discrimination: Emerging Applications of Epigenetics Pointing to the Limitations of Policies Against Genetic Discrimination

Autoren: Charles Dupras, Lingqiao Song, Katie M. Saulnier, Yann Joly
Veröffentlicht in: Frontiers in Genetics, Ausgabe 9, 2018, ISSN 1664-8021
Herausgeber: Frontiers Media
DOI: 10.3389/fgene.2018.00202

Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review

Autoren: Maaike Alblas, Kimberley B. Velt, Nora Pashayan, Martin Widschwendter, Ewout W. Steyerberg, Yvonne Vergouwe
Veröffentlicht in: Critical Reviews in Oncology/Hematology, Ausgabe 126, 2018, Seite(n) 92-99, ISSN 1040-8428
Herausgeber: Elsevier BV
DOI: 10.1016/j.critrevonc.2018.03.023

Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women’s Cancer: Points to Consider

Autoren: Emmanuelle Lévesque, Emily Kirby, Ineke Bolt, Bartha Maria Knoppers, Inez de Beaufort, Nora Pashayan, Martin Widschwendter
Veröffentlicht in: Public Health Genomics, 2018, Seite(n) 1-8, ISSN 1662-4246
Herausgeber: S. Karger AG
DOI: 10.1159/000492663

Epigenome-based cancer risk prediction: rationale, opportunities and challenges

Autoren: Martin Widschwendter, Allison Jones, Iona Evans, Daniel Reisel, Joakim Dillner, Karin Sundström, Ewout W. Steyerberg, Yvonne Vergouwe, Odette Wegwarth, Felix G. Rebitschek, Uwe Siebert, Gaby Sroczynski, Inez D. de Beaufort, Ineke Bolt, David Cibula, Michal Zikan, Line Bjørge, Nicoletta Colombo, Nadia Harbeck, Frank Dudbridge, Anne-Marie Tasse, Bartha M. Knoppers, Yann Joly, Andrew E. Teschendorf
Veröffentlicht in: Nature Reviews Clinical Oncology, Ausgabe 15/5, 2018, Seite(n) 292-309, ISSN 1759-4774
Herausgeber: Nature Publishing Group
DOI: 10.1038/nrclinonc.2018.30

What do European women know about their female cancer risks and cancer screening? A cross-sectional online intervention survey in five European countries

Autoren: Odette Wegwarth, Martin Widschwendter, David Cibula, Karin Sundström, Rosalba Portuesi, Ines Lein, Felix G Rebitschek
Veröffentlicht in: BMJ Open, Ausgabe 8/12, 2018, Seite(n) e023789, ISSN 2044-6055
Herausgeber: BMJ Publishing Group
DOI: 10.1136/bmjopen-2018-023789

Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges

Autoren: Nora Pashayan, Daniel Reisel, Martin Widschwendter
Veröffentlicht in: Personalized Medicine, Ausgabe 13/2, 2016, Seite(n) 93-95, ISSN 1741-0541
Herausgeber: Future Medicine Ltd.
DOI: 10.2217/pme.15.53

Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management

Autoren: Vit Weinberger, Marketa Bednarikova, David Cibula, Michal Zikan
Veröffentlicht in: Expert Review of Anticancer Therapy, Ausgabe 16/12, 2016, Seite(n) 1311-1321, ISSN 1473-7140
Herausgeber: Future Drugs Ltd.
DOI: 10.1080/14737140.2016.1247699

Non-peer reviewed articles (1)

Autonomy Challenges in Epigenetic Risk-Stratified Cancer Screening: How Can Patient Decision Aids Support Informed Consent?

Autoren: Maaike Alblas, Maartje Schermer, Yvonne Vergouwe, Ineke Bolt
Veröffentlicht in: Journal of Personalized Medicine, Ausgabe 9/1, 2019, Seite(n) 14, ISSN 2075-4426
Herausgeber: Jourmal of Personalized Medicine
DOI: 10.3390/jpm9010014